课题基金 / 基金详情

项目摘要

项目成果

JESSE ROWLEY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract Mitochondrial dysfunction is associated with numerous diseases, including disorders of thrombosis and hemostasis. Platelets inherit fully functional mitochondria from megakaryocytes, yet how megakaryocytes maintain mitochondrial integrity and function during their unique developmental process is unknown. Genetic studies have associated the mitochondrial maintenance and fusion protein Mitofusin 2 (MFN2) with platelet counts and cardiovascular disease. Our preliminary data show that loss of MFN2 in human platelets is associated with accelerated platelet death in vitro. Knockout of MNF2 in mice reduced platelet survival, and impaired hemostasis and thrombosis. Preliminary data suggest a mitochondrial role: loss of MFN2 disrupted mitochondrial morphology in megakaryocytes, and impaired mitochondrial function in platelets. In Aim 1 we test the hypothesis that MFN2 maintains mitochondrial integrity and function during megakaryocyte development to ensure platelets inherit fully functional and long-lived mitochondria. In Aim 2 we test the hypothesis that loss of MFN2 leads to platelet death, dysfunction, and altered hemostasis and thrombosis. Because MFN2 is especially important in adapting to metabolic stress, we will test each of these hypotheses under normal conditions and during metabolic stress. Each aim will have a mouse and human component: for mouse studies we will use platelet/megakaryocyte specific MFN2 knockouts, and for human studies we will utilize primary cells harboring a genetic variant that significantly reduces MFN2 expression in platelets. This work is significant because the results may lead to new approaches to target disorders of thrombosis and hemostasis, and improve platelet production and storage. This work is innovative: we will examine mitochondrial fusion, a novel pathway regulating platelet survival and function in health, during metabolic stress, and in transfused platelets. We will use innovative methods to examine mitochondrial function in new and circulatory aged platelets. Our studies will provide new insights into how MFN2 affects platelet death and dysfunction, an important step into understanding why human MFN2 variants are associated with platelet counts and cardiovascular disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluation of genetic variants affecting platelet function with CRISPR HDR in human megakaryocytes
  • 批准号:
    10737494
  • 项目类别:
  • 资助金额:
    $53.7万
  • 财政年份:
    2023
  • 负责人:
    JESSE ROWLEY
  • 依托单位:
Mitochondrial fusion protein MFN2 prevents platelet death and dysfunction
  • 批准号:
    10525224
  • 项目类别:
  • 资助金额:
    $38.13万
  • 财政年份:
    2019
  • 负责人:
    JESSE ROWLEY
  • 依托单位:
Mitochondrial fusion protein MFN2 prevents platelet death and dysfunction
  • 批准号:
    10308677
  • 项目类别:
  • 资助金额:
    $38.13万
  • 财政年份:
    2019
  • 负责人:
    JESSE ROWLEY
  • 依托单位:
The Platelet Metabolome in Obesity
  • 批准号:
    8539059
  • 项目类别:
  • 资助金额:
    $15.66万
  • 财政年份:
    2012
  • 负责人:
    JESSE ROWLEY
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: